Idexx Laboratories IDXX
NASDAQ IDXX
$518.00 +4.86 (+0.95%)
At close: Oct 9, 2026 · 4:00 PM EDT

Idexx Laboratories (IDXX) Income from Continuing Operations (2009 - 2026)

Updated

Idexx Laboratories (IDXX) recorded Income from Continuing Operations of $338.41 million in Q2 2026, up 15.1% from $293.99 million a year earlier and up 21.5% from the prior quarter.

Analysis

Idexx Laboratories (IDXX) Income from Continuing Operations (2009 - 2026) Analysis & Trends

On a TTM basis, Idexx Laboratories' Income from Continuing Operations came in at $1.14 billion as of Jun 30, 2026, up 15.6% year-over-year; for FY2025, it was $1.06 billion, up 19.3% from FY2024.

  • Annual Income from Continuing Operations has increased for three straight years, with a five-year compound annual growth rate of 12.7% (FY2020 to FY2025).
  • Across earlier years, Income from Continuing Operations came in at $887.87 million in FY2024 (+5.1%), $845.04 million in FY2023 (+24.4%), $679.09 million in FY2022 (-8.8%) and $744.84 million in FY2021 (+28.0%).
  • The Q2 2026 figure is the highest quarterly Income from Continuing Operations in data going back to Q2 2009.
  • On a year-over-year basis, Income from Continuing Operations has increased for eight consecutive quarters, with growth averaging 16.4% over the last eight quarters.
  • Peak year-over-year performance for Income from Continuing Operations in the last five years was growth of 69.9% in Q2 2023, against a decline of 34.9% in Q2 2022 at the low end.
  • Per Business Quant, the preceding three quarters came in at $278.45 million (Q1 2026), $248.19 million (Q4 2025) and $274.61 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Eli Lilly 1,109.58 Bn 1,078.16 Bn 19.71 Bn 7.10 Bn
2 Johnson & Johnson 630.16 Bn 548.69 Bn 17.26 Bn 5.53 Bn
3 AbbVie 488.57 Bn 461.73 Bn 12.70 Bn 3.62 Bn
4 Merck 359.15 Bn 313.58 Bn 12.21 Bn -1.34 Bn
5 Novartis Ag 274.32 Bn 238.71 Bn 11.24 Bn 5.28 Bn
6 Astrazeneca 246.73 Bn 220.50 Bn 12.86 Bn 3.09 Bn
7 Amgen 224.28 Bn 179.68 Bn 7.24 Bn 2.38 Bn
8 Gilead Sciences 187.60 Bn 161.71 Bn 6.22 Bn -10.50 Bn
9 Pfizer 161.13 Bn 108.08 Bn 10.94 Bn -246.00 Mn
10 Idexx Laboratories 40.86 Bn 40.07 Bn 779.09 Mn 338.41 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 338.41 Mn
Mar 31, 2026 278.45 Mn
Dec 31, 2025 248.19 Mn
Sep 30, 2025 274.61 Mn
Jun 30, 2025 293.99 Mn
Mar 31, 2025 242.68 Mn
Dec 31, 2024 216.15 Mn
Sep 30, 2024 232.84 Mn
Jun 30, 2024 203.30 Mn
Mar 31, 2024 235.58 Mn
Dec 31, 2023 194.52 Mn
Sep 30, 2023 212.23 Mn
Jun 30, 2023 224.24 Mn
Mar 31, 2023 214.05 Mn
Dec 31, 2022 172.21 Mn
Sep 30, 2022 180.94 Mn
Jun 30, 2022 131.98 Mn
Mar 31, 2022 193.97 Mn
Dec 31, 2021 162.77 Mn
Sep 30, 2021 175.18 Mn
API Access

Idexx Laboratories Income from Continuing Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=IDXX&period=max&api_key=YOUR_API_KEY